From Reactive Species to Clinical Decisions in Redox Medicine
Reactive oxygen, nitrogen, halogen, and sulphur species are context-dependent signals whose biological meaning is set by their source, subcellular location, and time course. Their mechanistic basis is now well described, and we have reviewed it elsewhere, yet clinical translation remains limited, and inadequate measurement is one of its most tractable obstacles, together with insufficient clinical validation and scarce outcome evidence. This review therefore condenses the mechanistic premise to what is needed to interpret a biomarker and then proposes that redox biomarkers be organised in two tiers. A first tier of systemic footprints, anchored by relatively stable markers such as urinary F2-isoprostanes and complemented by nitrative or chlorinative indices and by dynamic thiol redox couples, supports longitudinal monitoring and coarse stratification with assays that clinical laboratories can realistically run. A second, research-grade tier comprises compartment-resolved measurements in accessible cells, such as peroxiredoxin oxidation state and site-resolved cysteine proteomics (Tier 2a), and pathway-associated circulating indicators, such as the arginine to asymmetric dimethylarginine ratio, thiosulphate, and sulphane sulphur (Tier 2b), which carry different evidential burdens. None of these readouts is yet validated for clinical decision-making. We set out the analytical requirements that both tiers must satisfy, including precision, trueness, metrological traceability, commutable reference materials, external quality assessment, reference change values, and pre-analytical control. Applications are discussed across cardiometabolic, neurodegenerative, renal and respiratory disease, oncology, and sepsis. Finally, we outline how biomarker role, enrichment, and pharmacodynamic anchoring should be prespecified so that redox-targeted trials can demonstrate biological engagement rather than infer it, recognising that clinical utility will require prospective outcome-oriented studies.
Authors
- Celia Andrés (ORCID: https://orcid.org/0000-0003-1583-7439)
- José Manuel Pérez de la Lastra (ORCID: https://orcid.org/0000-0003-4663-5565)
- Celia María Curieses Andrés (ORCID: https://orcid.org/0000-0003-4731-6398)
- Elena Bustamante Munguira (ORCID: https://orcid.org/0000-0002-5657-9547)
- Eduardo Pérez Lebeña
Institutions
- Universidad de Valladolid (ES)
- Consejo Superior de Investigaciones Científicas (ES)
- Instituto de Productos Naturales y Agrobiología (ES)
- Hospital Clínico Universitario de Valladolid (ES)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/biomedicines14112675
- Primary Topic
- Redox biology and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 0.00